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The cotton rat model of respiratory syncytial virus (RSV) infection has been used for over 20 years to study the pathogenesis and potential therapy of RSV (7) . This animal model was invaluable in proving the protective efficacy of anti-RSV antibody (6) and led to the development of RSV immunoglobulin (RespiGam; Medimmune, Inc., Gaithersburg, Md.) and palivizumab (Synagis; Medimmune) for the prevention of severe RSV infection of the lower respiratory tract (1, 2, 5). These preparations have been less effective when used therapeutically (9, 10) . Recent experiments with cotton rats demonstrated that combined systemic therapy with palivizumab and triamcinolone acetonide, a potent glucocorticoid, greatly reduced inflammatory changes and viral replication in animals infected with RSV but that palivizumab alone reduced viral titers without altering the degree of inflammation (8) . Systemic triamcinolone acetonide is rarely used in the treatment of pediatric respiratory disease, and therefore we examined the comparative efficacies of triamcinolone acetonide, methylprednisolone, and dexamethasone when each was used in combination with palivizumab in the treatment of experimental RSV infection.
( Virus. A pool of the prototypic Long strain of RSV (American Type Culture Collection, Manassas, Va.) which contained 10 7.5 PFU/ml was used for all experiments. Pulmonary virus titers were determined by plaque assay as described previously (7) .
Monoclonal antibody and glucocorticoids. Palivizumab was provided by Medimmune, Inc. Triamcinolone acetonide (Steris Laboratories, Phoenix, Ariz.) was administered as a single daily intramuscular (i.m.) dose of 16 mg/kg of body weight, a dose previously found to be highly effective in reducing pulmonary pathology (8) . Dexamethasone (Elkins-Sinn, Cherry Hill, N.J.) was administered in a single daily intraperitoneal (i.p.) dose of 0.6 or 1.2 mg/kg. Methylprednisolone (SoluMedrol; Phamacia and Upjohn, Kalamazoo, Mich.) was administered in a total daily dose of 4 or 8 mg/kg divided into four equal i.p. injections.
Histopathology. Lungs were inflated to their normal volume with 10% formalin. Hematoxylin-and eosin-stained slides were prepared from coronal paraffin-embedded sections and scored for peribronchiolitis (inflammatory cells around small airways), interstitial pneumonitis (inflammatory cell infiltration and thickening of alveolar walls), and alveolitis (inflammatory cells within the alveolar spaces). Slides were scored in a blind manner by three investigators using a scale ranging from 0 (no inflammatory changes) to 100 (maximum inflammation).
Statistical analysis. A viral titer was expressed as the geometric mean Ϯ standard error for all animals in a group. The two-tailed Student t test, using summary data, was used to determine the significance of differences between groups. The number of histologic lesions was expressed as an arithmetic mean Ϯ the standard error of the numbers of lesions for all animals in a group. Statistical analysis of composite histology scores was not done, since the data are disparate.
Comparative efficacies of different steroids. Six groups of eight or nine cotton rats were intranasally infected with 10 6.5 PFU of RSV Long and given one i.m. dose of palivizumab (15 mg/kg) 3 days later. Five of these groups received glucocorticoid therapy as described above on days 3, 4, and 5 postinfection. All animals, including those in a seventh uninfected group, were sacrificed for histopathological evaluation on day 6 after infection, and the results are summarized in Fig. 1A . As we reported earlier, therapy with palivizumab alone did not reduce pathology (8) . Triamcinolone acetonide and either dose of methylprednisolone reduced the pathologic changes to nearly baseline levels. Dexamethasone at either dose was less effective in reducing inflammation, particularly peribronchiolitis. Representative lung photomicrographs are shown in Fig. 2 .
Recurrence of virus replication or pathologic changes. Four groups of 20 cotton rats each were infected intranasally with 10 6.5 PFU of RSV Long. On the third day postinfection, animals in three of the groups received one i.m. dose of palivizumab (15 mg/kg) and concurrent glucocorticoid therapy on days 3, 4, and 5 in the following doses: for triamcinolone acetonide, 16 mg/kg i.m. once daily; for methylprednisolone, 4 mg/kg administered as 1 mg/kg i.p. every 6 h; or for dexamethasone, 0.6 mg/kg i.p. once daily. Animals were sacrificed on days 6, 8, 10, 12, and 14 postinfection for viral titration and histopathology.
Inflammation following untreated RSV infection was significant on day 6 postinfection and slowly abated over the subsequent 8 days (Fig. 1B) . All three glucocorticoid-treated groups had greater reductions in pathology; no group had a recurrence of histopathology over the 2-week period. On day 6, 10 2.5 PFU of RSV per g was recovered from the lungs of untreated animals, while 10 3 PFU/g was recovered from the lungs of triamcinolone-palivizumab-treated animals on days 6 and 8 of experimental infection. No further viral replication was detected in any groups during the remainder of the experiment. This scant level of viral replication eliminated the need for comparative statistical analysis of viral titrations.
In recent years, there has been a realization that the therapy of certain infectious diseases needs to target both the infectious agent and host inflammation. The results of trials using glucocorticoids to treat RSV disease are mixed, with some trials suggesting the efficacy of such treatment and others showing no benefit (4). The types and doses of corticosteroids have been sufficiently varied to make the interpretation of results extremely difficult. A similar long-standing debate about the effectiveness of corticosteroid treatment of viral croup was resolved in 1989 when a meta-analysis of all reported clinical trials suggested that the type and dose of corticosteroid were critical factors in determining the outcome (3), a conclusion reinforced by the publication of a well-designed, double-blind, placebo-controlled study which demonstrated a significant benefit from a large dose of dexamethasone (11) . In this series of experiments, triamcinolone and methylprednisolone were more effective than dexamethasone and lacked adverse effects; they also reduced pulmonary histopathology in RSV-infected cotton rats by equal amounts. These experiments were conducted with drugs already licensed by the Food and Drug Administration and in common pediatric usage. The novelty of our approach is the combination of these two types of drugs, an antiviral agent along with an anti-inflammatory agent, to treat viral pneumonia. Though cotton rats do not exhibit overt clinical disease, this animal model has a proven track record of predicting the outcomes of several RSV interventions. We feel that the findings of this study demonstrating the efficacy and safety of our approach in the cotton rat model, provide the rationale for clinical trials of combined therapy.
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